Navigation Links
AMDL Announces Closing of Private Offering
Date:12/24/2007

TUSTIN, Calif., Dec. 24 /PRNewswire-FirstCall/ -- AMDL, Inc. (Amex: ADL), developer and marketer of tests for the early detection of cancer and other serious diseases, announced today that it has conducted the closing of its combined Regulation D/Regulation S private unit offering of 2,007,508 shares of common stock and warrants to purchase 1,003,755 shares of common stock, generating net proceeds of approximately $5,433,000. The shares of AMDL common stock were sold at $3.09 per share and the four year warrants included in the units are exercisable at $4.74 per share. Warrants to purchase an additional 200,751 shares were issued to AMDL's placement agents at the same exercise price. AMDL agreed to file a registration statement within 60 days of the closing to register the resale of the shares of common stock and the shares issuable on exercise of the warrants included in the units and the placement agent warrants. Spencer Clarke, LLC, a FINRA member broker dealer, acted as AMDL's principal placement agent for sales in the United States, and Galileo Asset Management, S.A., a member of the Association Romande des Intermediaries Financier, acted as AMDL's placement agent for sales outside of the United States.

Gary L. Dreher, President of AMDL, said: "The reception to the offering was gratifying under the current economic climate. These funds provide some of the additional working capital we need to expand Jade Pharmaceutical Inc.'s new business opportunities and product development efforts in China and for our other general working capital needs."

About AMDL

AMDL, Inc., headquartered in Tustin, California, with operations in Shenzhen, Jaingxi and Jilin China through its wholly owned subsidiary Jade Pharmaceutical Inc., is an international biopharma company. AMDL together with Jade engages in the development, manufacture and marketing of proprietary pharmaceutical and testing products. More information about AMDL and its products can be obt
'/>"/>

SOURCE AMDL, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
3. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
4. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
5. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
6. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
11. CNS Response Announces Fiscal Third Quarter 2007 Results

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)... , REYKJAVIK, Iceland, November.... (Nasdaq: DCGN ) today announced that it has rece...ing in the company,s common stock will be,suspende...e filed with the,Securities and Exchange Commissio...sting on Nasdaq, unless the company files an appea...
(Date:11/24/2009)... , REYKJAVIK, Iceland, November.... (Nasdaq: DCGN ) today announced the approval of ...tcy Court for the District of Delaware,(the "Bankr...petition for,relief under Chapter 11 of the United... , The orders issued by the Bankruptcy Co...
(Date:11/24/2009)... , SHANGHAI, Nov. 24 /PRNewswire-Asia/ ...od & Drug Administration (SFDA) has approved t...its oral insulin project,(Nodlin), an innovative i...roval allows Biolaxy to initiate its first phase I... characteristic of high blood glucose and poor,met...
(Date:11/24/2009)... , , Primary efficacy endpoint has been met ...endometrial cancer, , QUEBEC CITY, Nov. 24 /P...AQ: AEZS ; TSX: AEZ) (the "Company"), a global bi...py and oncology, today announced positive efficacy...oxic peptide conjugate, AEZS-108 (formerly AN-152)...
Breaking Biology Technology:deCODE Receives Delisting Notice From Nasdaq, Plans to Appeal 2deCODE Receives Delisting Notice From Nasdaq, Plans to Appeal 3deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 2deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 3Biolaxy Secures IND Approval for Oral Insulin 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 4
...orporation,announced today that it has entered int...HP, Nasdaq: SHPGY, TSX: SHQ), to jointly develop A...n in various gastrointestinal,("GI") disorders. Sh... of,AT-1001 outside of the United States and Japan...1001 in the United States and Japan., Under the t...
...f,directors of Abbott today declared a quarterly c...ks the 336th consecutive quarterly dividend to be ...yable Feb. 15, 2008, to,shareholders of record at ...as increased its dividend payout for 35 consecutiv...er this year -- and was named to the,2007 Fortune ...
...euticals, Inc. (Nasdaq: ISIS ) today announced th...rshall, J.D. to Chief Operating Officer,effective ...Chief Financial,Officer, and is a Director of the ...ppropriately reflects the scope,of Lynne,s respons...,Ph.D., Isis, President and CEO. "Lynne has been a...
Other Biology Technology:Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001 2Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001 3Isis Announces Appointment of B. Lynne Parshall as Chief Operating Officer 2Isis Announces Appointment of B. Lynne Parshall as Chief Operating Officer 3
(Date:11/25/2009)...isch, Head of the Cell Death Research Laboratory i... has been awarded the prestigious Johnson & Johnso... the cause of brain cell damage in Parkinson,s dis...entists in support of innovation and excellence in...nferred earlier this month at an event at the Hyat...
(Date:11/25/2009)...University assistant professors recently received ... to continue research beneficial to understanding ..., Christopher Blackwood, assistant professor in ... grants to support two separate research projects....Decomposer Communities and Functions from the Leaf...
(Date:11/24/2009)...rch Institute (LRI) today named 12 new grant recip... recognize innovative work across a broad spectrum...eativity, novelty, and potential to drive scientif...e the complex disease of systemic lupus. , The 2...searchers across the nation and include interdisci...
Breaking Biology News(10 mins):Johnson & Johnson award goes to research of the cause of brain cell damage in Parkinson's 2Kent State University professors focus research on the environment with grants totaling $890,000 2Lupus Research Institute announces 2009 novel research grants 2Lupus Research Institute announces 2009 novel research grants 3Schofield Media Names Brian Reshefsky Group President 56972 1Coast Dental Deploys Demandforce D3 Communications Platform 56970 1Coast Dental Deploys Demandforce D3 Communications Platform 56970 2Discovery May Pave Way to Better Diabetes Care 56967 1
...lephants dont carry photo identification, so scien...ndias Nature Conservation Foundation are providing...phic archive of individual elephants, which can he...veloped a unique photographic capture-recapture su...nts, specifically by the shape and size of their t...
...Antonio)Its been more than 100 years since anyone ...sen Sea, but that is about to change. Next month ...ence teacher will join a crew of 22 researchers fr...pedition. , The trip, funded by a $533,000 Natio...A, is designed to study the relationship of sea ic...
...sts have discovered a key protein in the toxic bra...yndrome (FXTAS), an inherited neurodegenerative di...of FXTAS, could help unravel the complex mechanism...s to target the protein. The research will be pub... , Fragile X tremor/ataxia syndrome was first rec...
Other Biology News:Male elephants get 'photo IDs' from scientists 2Texas researchers and educators head for Antarctica 2Scientists link fragile X tremor/ataxia syndrome to binding protein in RNA 2
...,• High specific activity and processivity r...erhang ,• Processes ,A thermostable DNA...rimer extension and other molecular biology applic...lot has been functionally tested for maximal activ...
...,• High specific activity and processivity r...verhang ,• Processes ,A thermostable DN...primer extension and other molecular biology appli... lot has been functionally tested for maximal acti...
Taq DNA Polymerase (Thermus aquaticus) from GE Healthcare, formerly Amersham Biosciences
Mango-Taq DNA Polymerase from Bioline
Biology Products: